Anzeige
Mehr »
Freitag, 13.02.2026 - Börsentäglich über 12.000 News
Die Kommerzialisierung der räumlichen Intelligenz in Billionen-Märkten beginnt jetzt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
415 Leser
Artikel bewerten:
(2)

Montagu: Tyber Medical, Intech and Resolve Surgical Technologies combine to form a next-generation solutions provider to the Medical Device industry

LONDON, Jan. 14, 2025 /PRNewswire/ -- Montagu announced today its intention to create a world-leading medical devices supplier by supporting the merger of Tyber Medical, Intech and Resolve Surgical Technologies ("Resolve").

As part of the transaction, Montagu entered into a definitive agreement to acquire Tyber Medical, an innovative medical device company providing private label development and manufacturing services to med-tech Original Equipment Manufacturers (OEMs). Subject to customary regulatory approvals and closing conditions, Tyber Medical will be combined with Montagu's existing investments in Resolve, a leading provider of contract device design, manufacturing, and lifecycle management services, as well as in Intech, a leader in the co-development and manufacturing of complex orthopaedic surgical devices.

The combined entity will offer a unique mix of proprietary market-cleared technologies, and development and manufacturing scale, that will enable its OEM customers to achieve unmatched speed to market and improve the resiliency and effectiveness of their supply chain. At the time of the merger, the platform will be a leading contract supplier of systems for Spine, Trauma, Extremities, Sports Medicine and Enabling Technologies, with plans to expand its pioneering innovation-led model into additional markets. The planned merger will support accelerated innovation and help improve standards of care for patients globally.

Jeff Tyber, Founder and CEO at Tyber Medical said: "Tyber Medical's proven track record of successful global launches, averaging 12 months from signing to launch, has revolutionized how our partners expand their portfolios and adapt to the evolving market dynamics. This strategic combination brings together the size, scale, and expertise of Intech, along with Resolve's deep knowledge in the Spine and Cardiothoracic fields. We are delighted to be partnering with Montagu, a leading investment firm in the private label OEM sector, and we share their vision of creating an industry champion."

"This unique combination represents a significant milestone, enhancing our ability to serve medical technology companies worldwide," said Laurent Pruvost, President and CEO of Intech. "By combining Intech's global manufacturing footprint and know-how with Resolve and Tyber's tailored solutions, we will establish ourselves as the undisputed partner of choice in the industry."

Megan Osorio, President and CEO of Resolve said: "Bringing innovation to market with speed and quality is of the utmost importance to our OEM customers. Joining forces will increase our ability to support their growth across the full range of orthopaedic implants & instruments by bringing the deep experience of our respective teams and scale of our manufacturing footprint together."

Adrien Sassi, Partner at Montagu said: "Montagu is proud to support the creation of this world-class medical device platform. The three organisations share similar passion and focus on delivering innovative, high-quality, reliable solutions to OEM customers, surgeons, and patients. We look forward to partnering with Jeff Tyber and his talented team, as well as extending our successful collaboration with Intech and Resolve."

Houlihan Lokey and Dechert LLP, respectively, acted as exclusive financial advisor and legal advisor to Tyber Medical. Weil Gotshal & Manges acted as legal advisor to Montagu, Intech and Resolve.

Media enquiries

Greenbrook: James Madsen and Cecilie Oerting
+44 20 7952 2000 | montagu@greenbrookadvisory.com

About Intech

Intech is a global leader in the manufacturing of orthopaedic devices and mission-critical components. With facilities in the USA, Europe, and Asia-Pacific, the group excels in producing surgical implants, instruments, cutting tools, handles, and sterilization containers. With innovation at heart, Intech is at the forefront of contract-design and contract-manufacturing in the field of Orthopaedics and Healthcare. Intech is also home to SMADE, its IoMT division that offers smart tracking of geolocation, sterilisation cycles, and usage of surgical containers on the field. For more information, visit https://intech-medical.com/.

About Resolve Surgical Technologies

Resolve Surgical Technologies is an industry-leading private label OEM that designs, develops and manufactures metal and polymer implants and instruments serving the orthopaedics, spine and cardiothoracic markets. Originally founded in 1992 as Pioneer Surgical Technology, Inc. and later known as the Metals division of RTI Surgical, Resolve became known for their innovative designs and engineering expertise. Today, Resolve Surgical focuses on creating value as an extension of our OEM partners' teams to deliver innovation, accelerate speed to revenue and drive lifecycle management with robust quality and regulatory support. For more information, visit www.resolvesurg.com.

About Tyber Medical LLC

Tyber Medical LLC is a leading orthopaedic device manufacturer providing rapid access to FDA-cleared and CE-marked, private label, portfolio-enhancing regulatory-approved orthopaedic implants for the spinal, extremity, and trauma markets. Since its founding in 2012, the company has released more than 50 spine, extremity, and trauma systems. Tyber Medical aims to develop and utilize differentiated bioengineered technologies, including surface treatments and coatings, to advance orthopaedic science. For more information, visit https://tybermedical.com/.

About Montagu

Montagu is a leading mid-market private equity firm, committed to finding and growing businesses that make the world work. Focussing on businesses with a must-have product or service in a structurally growing marketplace, Montagu brings proven growth capabilities to help companies achieve their ambitions and unlock their full potential. Montagu specialises in carve-out and other first time buyout investments and has deep expertise in five priority sectors: Healthcare, Financial Sector Services, Critical Data, Digital Infrastructure and Education. ESG forms an integral part of its strategy, and its commitment to responsible investment is fully integrated into its investment and value-creation process. Montagu partners with companies with enterprise values between €200 million and €1 billion and has €12bn assets under management. For additional information on Montagu, visit www.montagu.com

Cision View original content:https://www.prnewswire.co.uk/news-releases/tyber-medical-intech-and-resolve-surgical-technologies-combine-to-form-a-next-generation-solutions-provider-to-the-medical-device-industry-302350537.html

© 2025 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.